StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research note released on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Down 5.6 %
Galmed Pharmaceuticals stock opened at $0.32 on Friday. The business has a 50-day simple moving average of $0.34 and a 200 day simple moving average of $0.36. Galmed Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $1.29. The stock has a market cap of $1.59 million, a price-to-earnings ratio of -0.13 and a beta of 0.69.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last announced its earnings results on Thursday, May 30th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Read More
- Five stocks we like better than Galmed Pharmaceuticals
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- ScottsMiracle-Gro Stock Blooms After Investor Day Optimism
- Do ETFs Pay Dividends? What You Need to Know
- Leading Beverage Company’s Stock Bubbles Higher: Rally Ahead
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Can This Meme Stock Stage One Last Rally?
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.